messag updat estim follow result
follow recent announc sni collabor account methodolog
decreas price target increas pt
plan publish comprehens model updat
follow compani result report may
valuat risk
updat model follow earn reduc pt
pt base previous ep estim
lower pt target multipl peer group averag
account delay aducanumab file estim compani
vs question reason delay also support risk-
adjust npv forward price-to-earnings compar analysi yield
risk downsid risk includ failur alzheim asset pipelin
setback well faster expect shrinkag older portion ms
valuat risk
updat model rais pt
model updat take account new account partnership sni
increas pt due substanti out-performance compani across primari
product eylea dupix heavi attent compani gotten
effort drug kevzara attempt make antibodi
base success increas pe multipl
note previou valuat peer compani trade averag
multipl view line peer group peer compani
trade averag multipl believ trade
premium peer base upon momentum substanti potenti inher
key product increas multipl result pt although
pt repres potenti upsid current level maintain rate
period note extrem current market volatil
support npv-deriv pt arriv increas
pipelin valu base potenti growth libtayo nsclc type
cancer broken first time assign pipelin npv
reduc declin sale eylea base reduc
competit key competitor novn beovu npv/share
addit larg base increas potenti kevzara increas
npv/share antibodi collabor sni
risk downsid risk includ failur secur approv eylea/dupixent/
libtayo addit indic rapid complet implement
like seri regul
page analyst certif import disclosur
compani report guggenheim secur llc estim
page analyst certif import disclosur
interferon ms alzheimar yoy product rituxan/gazyva sale right incom interest net incom ep stock tax net incom includ non-cash stock ep includ stock share outstand mm except per share unitsyatin suneja
compani report guggenheim secur llc estim
page analyst certif import disclosur
yatin suneja chang chang product chang chang collabor global sale start record global sale record global sale record ex-u sale cemiplimab record share antibodi commerci share io commerci collabor eylea row chang chang eylea reimbursements/amort eylea row profit ou revenu research chang chang collabor manufactur partner product stock-bas up-front stock-bas non-gaap non-gaap income/expens rate incom net incom chang chang basic dilut cash per debt per sharecash flow gener mm except pre share unit
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic biogen inc
inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori biogen inc
creat bluematrix
rate price target histori inc
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
page analyst certif import disclosur
